Cargando…
Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review
Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL) characterized by a hallmark translocation of t (11; 14). CD10 negativity has been used to differentiate MCL from other NHL types; however, recently, there has been an increase in the number of reported cases of CD10-positive MCL. Thi...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298847/ https://www.ncbi.nlm.nih.gov/pubmed/37373354 http://dx.doi.org/10.3390/ijms241210207 |
_version_ | 1785064217680805888 |
---|---|
author | Castillo, Dani Ran Park, Daniel Jeon, Won Jin Joung, Bowon Lee, Jae Yang, Chieh Pham, Bryan Hino, Christopher Chong, Esther Shields, Andrea Nguyen, Anthony Brothers, Joel Liu, Yan Zhang, Ke K. Cao, Huynh |
author_facet | Castillo, Dani Ran Park, Daniel Jeon, Won Jin Joung, Bowon Lee, Jae Yang, Chieh Pham, Bryan Hino, Christopher Chong, Esther Shields, Andrea Nguyen, Anthony Brothers, Joel Liu, Yan Zhang, Ke K. Cao, Huynh |
author_sort | Castillo, Dani Ran |
collection | PubMed |
description | Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL) characterized by a hallmark translocation of t (11; 14). CD10 negativity has been used to differentiate MCL from other NHL types; however, recently, there has been an increase in the number of reported cases of CD10-positive MCL. This warrants further investigation into this rarer immunophenotype and its clinical significance. BCL6, which is a master transcription factor for the regulation of cell proliferation and key oncogene in B cell lymphomagenesis, has been reported to have co-expression with CD10 in MCL. The clinical significance of this aberrant antigen expression remains unknown. We conducted a systematic review by searching four databases and selected five retrospective analyses and five case series. Two survival analyses were conducted to determine if BCL6 positivity conferred a survival difference: 1. BCL6+ vs. BCL6− MCL. 2. BCL6+/CD10+ vs. BCL6−/CD10+ MCL. Correlation analysis was conducted to determine if BCL6 positivity correlated with the Ki67 proliferation index (PI). Overall survival (OS) rates were performed by the Kaplan–Meier method and log-rank test. Our analyses revealed that BCL6+ MCL had significantly shorter overall survival (median OS: 14 months vs. 43 months; p = 0.01), BCL6+/CD10+ MCL had an inferior outcome vs. BCL6+/CD10− MCL (median OS: 20 months vs. 55 months p = 0.1828), BCL6+ MCL had significantly higher percentages of Ki67% (Ki67% difference: 24.29; p = 0.0094), and BCL6 positivity had a positive correlation with CD10+ status with an odds ratio 5.11 (2.49, 10.46; p = 0.0000286). Our analysis showed that BCL6 expression is correlated with CD10 positivity in MCL, and BCL6 expression demonstrated an inferior overall survival. The higher Ki67 PI in BCL6+ MCL compared to BCL6− MCL further supports the idea that the BCL6+ immunophenotype may have prognostic value in MCL. MCL management should consider incorporating prognostic scoring systems adjusted for BCL6 expression. Targeted therapies against BCL6 may offer potential therapeutic options for managing MCL with aberrant immunophenotypes. |
format | Online Article Text |
id | pubmed-10298847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102988472023-06-28 Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review Castillo, Dani Ran Park, Daniel Jeon, Won Jin Joung, Bowon Lee, Jae Yang, Chieh Pham, Bryan Hino, Christopher Chong, Esther Shields, Andrea Nguyen, Anthony Brothers, Joel Liu, Yan Zhang, Ke K. Cao, Huynh Int J Mol Sci Review Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL) characterized by a hallmark translocation of t (11; 14). CD10 negativity has been used to differentiate MCL from other NHL types; however, recently, there has been an increase in the number of reported cases of CD10-positive MCL. This warrants further investigation into this rarer immunophenotype and its clinical significance. BCL6, which is a master transcription factor for the regulation of cell proliferation and key oncogene in B cell lymphomagenesis, has been reported to have co-expression with CD10 in MCL. The clinical significance of this aberrant antigen expression remains unknown. We conducted a systematic review by searching four databases and selected five retrospective analyses and five case series. Two survival analyses were conducted to determine if BCL6 positivity conferred a survival difference: 1. BCL6+ vs. BCL6− MCL. 2. BCL6+/CD10+ vs. BCL6−/CD10+ MCL. Correlation analysis was conducted to determine if BCL6 positivity correlated with the Ki67 proliferation index (PI). Overall survival (OS) rates were performed by the Kaplan–Meier method and log-rank test. Our analyses revealed that BCL6+ MCL had significantly shorter overall survival (median OS: 14 months vs. 43 months; p = 0.01), BCL6+/CD10+ MCL had an inferior outcome vs. BCL6+/CD10− MCL (median OS: 20 months vs. 55 months p = 0.1828), BCL6+ MCL had significantly higher percentages of Ki67% (Ki67% difference: 24.29; p = 0.0094), and BCL6 positivity had a positive correlation with CD10+ status with an odds ratio 5.11 (2.49, 10.46; p = 0.0000286). Our analysis showed that BCL6 expression is correlated with CD10 positivity in MCL, and BCL6 expression demonstrated an inferior overall survival. The higher Ki67 PI in BCL6+ MCL compared to BCL6− MCL further supports the idea that the BCL6+ immunophenotype may have prognostic value in MCL. MCL management should consider incorporating prognostic scoring systems adjusted for BCL6 expression. Targeted therapies against BCL6 may offer potential therapeutic options for managing MCL with aberrant immunophenotypes. MDPI 2023-06-16 /pmc/articles/PMC10298847/ /pubmed/37373354 http://dx.doi.org/10.3390/ijms241210207 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Castillo, Dani Ran Park, Daniel Jeon, Won Jin Joung, Bowon Lee, Jae Yang, Chieh Pham, Bryan Hino, Christopher Chong, Esther Shields, Andrea Nguyen, Anthony Brothers, Joel Liu, Yan Zhang, Ke K. Cao, Huynh Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review |
title | Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review |
title_full | Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review |
title_fullStr | Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review |
title_full_unstemmed | Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review |
title_short | Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review |
title_sort | unveiling the prognostic significance of bcl6+/cd10+ mantle cell lymphoma: meta-analysis of individual patients and systematic review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298847/ https://www.ncbi.nlm.nih.gov/pubmed/37373354 http://dx.doi.org/10.3390/ijms241210207 |
work_keys_str_mv | AT castillodaniran unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview AT parkdaniel unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview AT jeonwonjin unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview AT joungbowon unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview AT leejae unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview AT yangchieh unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview AT phambryan unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview AT hinochristopher unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview AT chongesther unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview AT shieldsandrea unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview AT nguyenanthony unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview AT brothersjoel unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview AT liuyan unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview AT zhangkek unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview AT caohuynh unveilingtheprognosticsignificanceofbcl6cd10mantlecelllymphomametaanalysisofindividualpatientsandsystematicreview |